These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 38231480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C, Zhang Y, Yang J, Xu Y, Deng T, Li Y, Xu S, Wang S, Wang P.
    Cell Commun Signal; 2024 Jul 08; 22(1):355. PubMed ID: 38978049
    [Abstract] [Full Text] [Related]

  • 3. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.
    Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, Bidet A, Martineau D, Fernandez S, Leguay T, Pigneux A, Vigon I, Pasquet JM, Desplat V.
    Clin Cancer Res; 2021 Nov 01; 27(21):6012-6025. PubMed ID: 34400415
    [Abstract] [Full Text] [Related]

  • 4. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK, Chatterjee A, Scarpa M, Bailey CM, Niyongere S, Singh P, Mustafa Ali MK, Kapoor S, Wang Y, Silvestri G, Baer MR.
    Cancer Res Commun; 2024 Feb 16; 4(2):431-445. PubMed ID: 38284896
    [Abstract] [Full Text] [Related]

  • 5. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
    Wu S, Liu F, Gai Y, Carter J, Edwards H, Hüttemann M, Wang G, Li C, Taub JW, Wang Y, Ge Y.
    Leuk Res; 2024 Sep 16; 144():107547. PubMed ID: 38968731
    [Abstract] [Full Text] [Related]

  • 6. In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.
    Carranza-Aranda AS, Jave-Suárez LF, Flores-Hernández FY, Huizar-López MDR, Herrera-Rodríguez SE, Santerre A.
    Mol Med Rep; 2024 Dec 16; 30(6):. PubMed ID: 39392050
    [Abstract] [Full Text] [Related]

  • 7. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J.
    Cell Rep Med; 2024 Jul 16; 5(7):101645. PubMed ID: 39019012
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
    Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung YK, Shah NP, Li HY.
    Eur J Med Chem; 2024 Jan 15; 264():115977. PubMed ID: 38056299
    [Abstract] [Full Text] [Related]

  • 11. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
    Moore AS, Faisal A, Mak GWY, Miraki-Moud F, Bavetsias V, Valenti M, Box G, Hallsworth A, de Haven Brandon A, Xavier CPR, Stronge R, Pearson ADJ, Blagg J, Raynaud FI, Chopra R, Eccles SA, Taussig DC, Linardopoulos S.
    Blood Adv; 2020 Apr 14; 4(7):1478-1491. PubMed ID: 32282883
    [Abstract] [Full Text] [Related]

  • 12. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, Peleteiro Raíndo A, Cid López M, Díaz Arias JÁ, Ferreiro Ferro R, Antelo Rodríguez B, González Pérez MS, Albors Ferreiro M, Alonso Vence N, Pérez Encinas MM, Bello López JL, Martinelli G, Cerchione C.
    Minerva Med; 2020 Oct 14; 111(5):427-442. PubMed ID: 32955823
    [Abstract] [Full Text] [Related]

  • 13. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
    Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP.
    Blood; 2013 Apr 18; 121(16):3165-71. PubMed ID: 23430109
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.
    J Clin Oncol; 2013 Oct 10; 31(29):3681-7. PubMed ID: 24002496
    [Abstract] [Full Text] [Related]

  • 15. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK, Perl AE, Hill JE, Rosales M, Bahceci E, Levis MJ.
    Cancer Med; 2021 Feb 10; 10(3):797-805. PubMed ID: 33340276
    [Abstract] [Full Text] [Related]

  • 16. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE.
    Cancer; 2014 Jul 15; 120(14):2142-9. PubMed ID: 24737502
    [Abstract] [Full Text] [Related]

  • 17. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, Wang F, Naren D, Cui Y, Liu X, Qu Y, Luo H, Yang Y, Wei H, Guo Y.
    Biochem Pharmacol; 2021 Jun 15; 188():114538. PubMed ID: 33831397
    [Abstract] [Full Text] [Related]

  • 18. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 19. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
    Darici S, Jørgensen HG, Huang X, Serafin V, Antolini L, Barozzi P, Luppi M, Forghieri F, Marmiroli S, Zavatti M.
    Adv Biol Regul; 2023 Aug 03; 89():100974. PubMed ID: 37245251
    [Abstract] [Full Text] [Related]

  • 20. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.